Claims
- 1. A method for raising serum HDL cholesterol levels comprising adminstering an effective HDL-raising amount of an LXR receptor ligand to a patient in need of such treatment.
- 2. The method of claim 1, wherein the LXR receptor is an LXRα receptor.
- 3. The method of claim 1, wherein the LXR receptor is an LXRβ receptor.
- 4. The method of claim 1, wherein the ligand is an agonist.
- 5. The method of claim 1, wherein the ligand is an antagonist.
- 6. The method of claim 1, wherein the ligand is a partial agonist.
- 7. The method of claim 2, wherein the ligand is an agonist.
- 8. The method of claim 2, wherein the ligand is an antagonist.
- 9. The method of claim 2, wherein the ligand is a partial agonist.
- 10. The method of claim 3, wherein the ligand is an agonist.
- 11. The method of claim 3, wherein the ligand is an antagonist.
- 12. The method of claim 3, wherein the ligand is a partial agonist.
- 13. The method of claim 1 wherein the LXR ligand binds with greater affinity to an LXR receptor than to a PPAR receptor.
- 14. The method of claim 13 wherein the LXR ligand has an IC50 less than or equal to 100 nM for at least one of an LXR receptor selected from LXRα and LXRβ, and an IC50 equal to or greater than 1 μM for each of the PPARα, PPARγ and PPARδ receptors.
- 15. The method of claim 14 wherein the LXR ligand has an IC50 equal to or greater than 10 μM for each of the PPARα, PPARγ and PPAR6 receptors.
- 16. A method for preventing or reducing the risk of developing atherosclerotic disease comprising administering an HDL-raising amount of an LXR receptor ligand to a patient in need of such treatment.
- 17. A method for treating atherosclerotic disease comprising administering an HDL-raising amount of an LXR receptor ligand to a patient in need of such treatment.
- 18. A method for preventing or reducing the risk of occurrence or recurrence of an atherosclerotic disease event comprising administering an HDL-raising amount of an LXR receptor ligand to a patient in need of such treatment.
- 19. A method for stimulating the expression of the ABC1 gene and thereby raising serum HDL cholesterol levels comprising administering an LXR ligand in an amount capable of stimulating expression of the ABC 1 gene to a patient in need of such treatment.
- 20. A method for stimulating cholesterol efflux comprising administering a therapeutically effective amount of an LXR receptor ligand to a patient in need of such treatment.
- 21. The compound 4,5-dihydro-1-(3-(3-trifluoromethyl-7-propyl-benzisoxazol-6-yloxy)propyl)-2,6-pyrimidinedione.
- 22. A compound having the following structural formula
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional application S No. 60/170,403, filed Dec. 13, 1999 and U.S. provisional application S No. 60/223,049, filed Aug. 4, 2000, herein incorporated by reference in its entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60170403 |
Dec 1999 |
US |
|
60223049 |
Aug 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09716554 |
Nov 2000 |
US |
Child |
10261710 |
Oct 2002 |
US |